Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

ClinicalTrials.gov ID: NCT02037256

Public ClinicalTrials.gov record NCT02037256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients

Study identification

NCT ID: NCT02037256
Recruitment status: Completed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Enrollment: 23 participants

Conditions and interventions

Conditions

Interventions

autologous hematopoietic stem cell transplantation Procedure
bortezomib Drug
filgrastim Biological

Procedure · Drug · Biological

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 30, 2011
Primary completion: Jan 20, 2015
Completion: Jan 20, 2015
Last update posted: May 9, 2021

2011 – 2015

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02037256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 9, 2021 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02037256 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →